Search clinical trials for: Sitagliptin plus metformin XR

Total 415 results

Merck Sharp & Dohme LLC

Completed

A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)

Type 2 Diabetes Mellitus
Woman's
Novo Nordisk A/S

Completed

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Type 2 Diabetes Mellitus | Metabolic Syndrome | Impaired Glucose Tolerance | Gestational Diabetes Mellitus | Disorder of Glucose Regulation

United States
AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

Diabetes Mellitus

United States
AstraZeneca

Completed

Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil

Type 2 Diabetes Mellitus

Brazil
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy

Diabetes Mellitus, Type II
AstraZeneca
Bristol-Myers Squibb

Completed

A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration (SAXA)

Type 2 Diabetes Mellitus(T2DM)

China
AstraZeneca

Terminated

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

Type 2 Diabetes Mellitus

United States
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
AstraZeneca

Withdrawn

BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

Type 2 Diabetes

Brazil
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)

Type 2 Diabetes Mellitus
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
Woman's
AstraZeneca

Completed

Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis (BMS-AZPCOS)

Polycystic Ovary Syndrome | Disorder of Glucose Regulation

United States
Cook County Health
Bristol-Myers Squibb

Completed

Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

Hyperglycemia | Diabetes Mellitus Type 2

United States
AstraZeneca

Completed

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

Type 2 Diabetes

United States, Argentina, Mexico, Israel
University of Guadalajara

Recruiting

Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity

Obesity

Mexico
AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

Diabetes Mellitus

United States
Bristol-Myers Squibb

Completed

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

South Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Merck KGaA, Darmstadt, Germany

Completed

Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes (CONSENT)

Diabetes Mellitus, Type 2

Germany
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Recruiting

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
The University of Queensland

Recruiting

Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

Autosomal Dominant Polycystic Kidney Disease

Australia
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
AstraZeneca

Completed

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Healthy Subjects in Fasted and Fed State

Brazil
Dexa Medica Group

Completed

PCOS Treatment Using DLBS3233, Metformin, and Combination of Both (POSITIF)

Insulin Resistance | Polycystic Ovary Syndrome (PCOS)

Indonesia
Dexa Medica Group

Completed

Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome (PCOS)

Indonesia
Merck Sharp & Dohme LLC

Completed

Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)

Diabetes Mellitus, Type 2
Handok Inc.

Completed

A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate Drugs

Healthy Volunteers

Korea, Republic of
AstraZeneca

Completed

Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Puerto Rico, Germany, Hungary
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Type 2 Diabetes Mellitus
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Not yet recruiting

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Type 2 Diabetes (Adult Onset)

United States
NYU Langone Health

Completed

Metformin Prostate Cancer Adjuvant Trial

Prostate Cancer | Prostate Cancer Recurrent

United States
AstraZeneca

Completed

Bioequivalence Study

Diabetes

United States
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Type 2 Diabetes
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
AstraZeneca
Bristol-Myers Squibb

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Diabetes Mellitus, Type 2

United States, Mexico, Canada, United Kingdom, India, Belgium, Taiwan
Merck KGaA, Darmstadt, Germany

Completed

Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study

Healthy

Indonesia
Baylor College of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes

Type 1 Diabetes

United States
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

GXR RM (Glucophage® Extended Release Reduced Mass) 500 Milligram (mg) Korea Bioequivalence (BE) Study

Healthy

Korea, Republic of
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Completed

GXR RM China BE Study (Darmstadt - Jiangsu)

Healthy

Germany
Bristol-Myers Squibb

Completed

Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients

Type 2 Diabetes Mellitus

China
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Bioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female Subjects

United States
Merck Sharp & Dohme LLC

Completed

Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)

Type 2 Diabetes Mellitus
AstraZeneca

Completed

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

Korea, Republic of, Mexico, South Africa, United States, Canada, Puerto Rico, Poland, Romania
Boehringer Ingelheim
Eli Lilly and Company

Completed

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Healthy

Germany
Shionogi

Completed

Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Woman's
Pfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...

Withdrawn

Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer (METBC)

Insulin Resistance | Breast Cancer Stage | Racial Bias

United States

3

Subscribe